Recombinant human growth hormone treatment in Down syndrome: The Troina experience

L. Ragusa, A. Alberti, C. Proto, C. Romano, F. Colabucci

Research output: Contribution to journalArticlepeer-review


The authors studied 40 subjects with Down syndrome (sDS), aged 1.6-19.6 years, in order to evaluate their growth hormone (GH) secretion. The clonidine test and the insulin tolerance test were performed in all sDS. In case of discordant results (low/normal), the 24-hour integrated concentration of growth hormone or the growth-hormone-releasing hormone plus pyridostigmine test were carried out. Twenty-one sDS showed abnormal GH secretion. Nine of them were given human recombinant GH (rhGH) ranging in time from 6 months to 3 years. Seven rhGH-treated sDS increased their starting centile, calculated immediately before therapy. L-Thyroxine was administered to sDS showing abnormally high TSH values, with prompt normalization. Thus, rhGH treatment seems to be effective in increasing the final height of GH-insufficient sDS.

Original languageEnglish
Pages (from-to)158-164
Number of pages7
JournalDevelopmental Brain Dysfunction
Issue number2-3
Publication statusPublished - 1996


  • Down syndrome
  • Growth hormone
  • rhGH treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Recombinant human growth hormone treatment in Down syndrome: The Troina experience'. Together they form a unique fingerprint.

Cite this